Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease
Acumen will show new test results for an Alzheimer's medicine in 2026. When companies share trial data, watch if the results look safe and effective.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.